首页> 美国卫生研究院文献>In Vivo >Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer
【2h】

Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer

机译:肿瘤浸润淋巴细胞可预测IV期大肠癌患者的化学治疗结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background/Aim: The anticancer immune response has been reported to contribute to the success of chemotherapy. The aim of this study was to evaluate the significance of the measurement of tumor-infiltrating lymphocytes (TILs) in the primary tumor using the method proposed by the International TILs Working Group as a prognostic marker of chemotherapeutic outcomes in patients with stage IV colorectal cancer (CRC). Patients and Methods: A total of 57 patients with stage IV CRC who underwent palliative chemotherapy after resection of the primary tumor were enrolled. Hematoxylin and eosin (H-E)-stained tumor sections were used for the evaluation of TILs. The density of TILs was assessed by measuring the area occupied by mononuclear inflammatory cells over the total stromal area at the invasive margin. Immunohistochemistry for CD8 was also performed, and the number of immunoreactive cytotoxic T-lymphocytes (CTLs) at the invasive margin was counted. Results: Thirty patients were classified into the high-TILs group, and 27 patients were classified into the low-TILs group. The high-TILs group had a significantly higher chemotherapeutic response rate (79.3% vs. 48.1%, p=0.025) and better progression-free survival (median survival time: 10.1 m vs. 7.3 m, p=0.0133) than the low-TILs group. Furthermore, the high-TILs group had a significantly better overall survival than the low-TILs group (median survival time: 35.5 m vs. 22.4 m, p=0.0221). The density of TILs evaluated using the H-E-stained sections showed a strong association with the number of CTLs (p<0.001). Conclusion: The measurement of TILs in the primary tumor using the method proposed by the International TILs Working Group can be used as a prognostic marker of the clinical effectiveness of palliative chemotherapy in patients with stage IV CRC
机译:背景/目的:据报道,抗癌免疫反应有助于化学疗法的成功。这项研究的目的是使用国际TILs工作组提出的方法评估原发肿瘤中肿瘤浸润淋巴细胞(TILs)作为IV期大肠癌患者化疗结果的预后指标( CRC)。患者和方法:共纳入57例IV期CRC的患者,这些患者在切除原发肿瘤后接受了姑息化疗。将苏木精和曙红(H-E)染色的肿瘤切片用于TIL的评估。通过测量在侵入边缘处单核炎性细胞在总基质面积上占据的面积来评估TIL的密度。还进行了CD8的免疫组织化学分析,并计算了浸润边缘的免疫反应性细胞毒性T淋巴细胞(CTL)的数量。结果:30例患者分为高TILs组,27例患者分为低TILs组。高TILs组的化疗反应率明显高于低TILs组(79.3%vs. 48.1%,p = 0.025)和无进展生存期(中位生存时间:10.1 m vs. 7.3 m,p = 0.0133)。 TILs组。此外,高TILs组的总生存期明显低于低TILs组(中位生存时间:35.5 m vs. 22.4 m,p = 0.0221)。使用H-E染色切片评估的TIL密度与CTL数量密切相关(p <0.001)。结论:采用国际TILs工作组提出的方法测量原发肿瘤中的TILs可作为IV期CRC患者姑息化疗临床疗效的预后指标

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号